No Data
No Data
Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390) Surges 9.6%; Retail Investors Who Own 51% Shares Profited Along With Insiders
Xinbang Pharmaceuticals: Report for the third quarter of 2024
Guizhou Xinbang Pharmaceutical (002390.SZ) released its performance for the first three quarters, with a net income of 0.177 billion yuan, a year-on-year decrease of 28.38%.
Guizhou Xinbang Pharmaceutical (002390.SZ) released its third quarter report for 2024. In the first three quarters, the company achieved revenue...
Guizhou Xinbang Pharmaceutical (SZSE:002390) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Increases 7.7% This Past Week
Does Guizhou Xinbang Pharmaceutical (SZSE:002390) Have A Healthy Balance Sheet?
Guizhou Xinbang Pharmaceutical (002390.SZ): Its hospital offers testing services such as lymphocyte subgroups, lymphocyte activation, dendritic cells, cell apoptosis, and leukemia immune analysis.
Guizhou Xinbang Pharmaceutical (002390.SZ) stated on the investor interaction platform that its hospitals have testing services for lymphocyte subsets, lymphocyte activation, dendritic cells, cell apoptosis, and leukemia immunological analysis.
No Data
No Data